ArticleBMC cancer2022

Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.

Richard Dillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.